IJCRR - 14(17), September, 2022
Pages: 01-06
Formulation and Evaluation of Euterpeoleracea In-Situ Gel for Better Treatment of Conjunctivitis
Author: Kanuri Spandana, Ramineni Shireesh Kiran, Ganti Subrahmanya Sharma, Tadikonda Rama Rao
Category: Healthcare
[Download PDF]
Abstract:
Introduction: This study is to formulate the Euterpe Oleracea in-situ gel for better treatment of conjunctivitis. The Euterpe Oleracea ophthalmic drug solution can treat the ocular infections effectively.
Aim: Formulation and evaluation of Eutepe Oleracea in-situ gel for better treatment of conjunctivitis
Methodology: Euterpe Oleracea drug containing in-situ gel prepared by using different polymers like carbopol-940, HPMC K15, HPMC K100, HPMC K4M, as a pH triggered gelling system, these polymers are used to controlled release to increase bioavailability.
Result: After the formulation prepared it will undergo evaluation i.e. visual appearance, pH, clarity checking, gel capacity, drug content and rheological studies, in-vitro drug release studies, sterility testing were determined. The prepared in situ gel was clear and transparent, it is having good gelling capacity.
Conclusion: The drug content of these formulations was determined to be 98%. Developed formulation was stable, and non-irritant, effective therapeutically it can be release in the form of sustained release.
Keywords: Euterpe Oleracea, HPMC, Citric acid, Disodium hydrogen phosphate, Tween-80, Benzalkonium chloride
Citation:
Kanuri Spandana, Ramineni Shireesh Kiran, Ganti Subrahmanya Sharma, Tadikonda Rama Rao. Formulation and Evaluation of Euterpeoleracea In-Situ Gel for Better Treatment of Conjunctivitis International Journal of Current Research and Review. 14(17), September, 01-06
References:
1. Saini R. In-situ gels- A New Trends in ophthalmic drug delivery system. IJPSR,2015:6(05);886-890.
2. Dol H. Formulation and evaluation of In-situ Ophthalmic gels of Moxifloxacin Hydrochloride. The Pharma Innov J.
2014;3(5):60-66.
3. Agarwal K. In-situ gel formation for ocular drug delivery system, Asian J Bio Pharm sci. 2011;1(4):1-7.
4. Rathore K.S. ‘’In situ gelling ophthalmic drug delivery system: An overview’’, Int J Pharm sci;2010,Vol,2, supl 4,30-34.
5. Mali N.M, Hajare A.A., In-situ gel forming system for sustained ocular drug delivery. Eur industrial pharmacy. 2010;5, 17-20.
6. Wagh VD. Polymers used in ocular dosage form and drug delivery system. Asian J Pharm 2008;2(1)
7. Jain SP. In-situ ophthalmic gel for Ciprofloxacin Hydrochloride for once a day sustained delivery, drug development Ind Pharm, 2008, 34, 445-452.
8. Basavaraj K. In-situ -forming hydrogels for sustained ophthalmic drug delivery 2007;122:119.
9. Doijad RC. Sustained ophthalmic delivery of gatifloxacin from in situ gelling system, Indian J Pharma sci, 2006, 68,814-818.
10. Gaudana R. Recent perspectives in ocular drug delivery, Pharmaceutical Research, 2009; vol.26, no.5, 1197-1216.
11. Chrysanthi L, Skevaki. Treatment of viral conjunctivitis with antiviral drugs. Drugs,2011; 71(3): 331-347.
12. Pacheco-palencia LA, Talcott ST. Chemical stability of acai fruit anthocyanins as influenced by naturally occurring and externally added polyphenolic cofactors in model systems, food chemistry, 2010; 118(1):17-25.
13. Kang J. Flavonoids from acai pulp and their antioxidant and anti- inflammatory activities. Food chem, 2011; 128(1): 152-157.
14. Mahesh N, Hajare A, Ion activated in situ gel system for ophthalmic delivery of Moxifloxacin hydrochloride. Lat. Am. J.
Pharm 2010; 29(6), 876-882.
15. Mudgil M. Nanotechnology: a new approach for ocular drug delivery system, IJPPS 2012; vol.4, no.2,pp. 105-112.
16. Tangri P, Khurana S, Basics of ocular drug delivery system, Int J Res Pharm Biomed Sci , 2011; vol.2, no.4, pp.1541-1552.
17. Venkatesh N.P, Liladhar, In situ gel based drug delivery system. 2011; Current drug therapy,6(3),213-222.
18. Jain SP. In situ ophthalmic gel of ciprofloxacin hydrochloride for once a day sustained delivery. Dug development and industrial pharmacy,2008; vol.34.
19. Brittain HG. Analytical profiles of drug substances and excipients. Elsevier 23: 321-361.
20. Rathi V.M, Murthy S.I. Allergic conjunctivitis. Community eye Health,2017. 30(99),7-10.
21. Shen J, Gan L, Zhu C. Novel NSAIDs ophthalmic formulation: Flubiprofen axetil emulsion with low irritancy and improved anti-inflammation effect, Int. J. Pharm, 2008; vol.361, no.1-2, pp. 222-229.
22. Amir A. Azari MD, Arabi A, MD, Conjunctivitis: A systemic review, Vision Research is J Ophthalmic. 2000; 15(3):372-395.
23. Vini R. Ocular Camouflage adoption for an Anophthalmic Anthrophobic Patient, IJCRR - Vol 13 Issue 10, May, 2021; page no. 11-15.
24. Sahane NK, Banarjee SK. Ocular Inserts: A Review, IJCRR – Vol 02 Issue 01, January, 2010, page no. 03-16.
|